Omega Therapeutics gains as dosing begins in cancer therapy study

Omega Liquidating

27/10/2022 16:50

** Shares of Omega Therapeutics Inc  OMGA.O  up ~3% at $5.74
    ** Co says first patient has been dosed in an early- to
mid-stage trial of its experimental therapy, OTX-2002
 urn:newsml:reuters.com:*:nPn1J9rvza
    ** OTX-2002 is being studied for treating a type of liver
cancer and other solid tumors associated with overexpression of
a gene known as c-Myc
    ** Study is expected to enroll nearly 190 patients at
clinical trial sites in the United States, Asia and Europe -
OMGA    
    ** Including session moves, stock is down ~49% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))